The earnings call highlights significant progress in OpRegen and OPC1 programs, coupled with a major manufacturing milestone that positions Lineage for further growth and partnerships. However, uncertainties around Genentech's decision-making timeline and data access, alongside potential enrollment challenges for OPC1, present notable concerns.

Company Guidance -

Q2 2025

During the first quarter 2025 conference call, Lineage Cell Therapeutics provided guidance on several key metrics and developments. The company reported total revenues of $1.5 million, a slight increase from the previous year's $1.4 million, with operating expenses of $8 million, slightly down from $8.1 million in 2024. The net loss was reduced to $4.1 million, or $0.02 per share, compared to a net loss of $6.5 million, or $0.04 per share, in the same period of 2024. Cash reserves stood at $47.9 million, expected to support operations until Q1 2027. Lineage highlighted their manufacturing capabilities, potential partnerships, and upcoming Phase 2a and 1/2a clinical data for their OpRegen program. Additionally, they discussed advancements in the OPC1 program for spinal cord injury, aiming to begin patient enrollment in June 2025.

OpRegen Program Progress

OpRegen, an allogeneic RPE cell transplant for dry AMD, shows promising results with anatomical and functional benefits lasting up to two years from one-time surgical delivery. The Phase 2a GAlette Study is progressing well, with Genentech continuing to invest in the program by acquiring RMAT designation and proprietary surgical delivery devices.

Manufacturing Milestone Achieved

Lineage achieved a GMP production run capable of producing millions of doses of product from a single starting cell line, demonstrating capability across multiple cell types and lines. This positions the company for new partnership opportunities.

OPC1 Program Advancements

A new delivery device for OPC1, designed to enhance safety and usability, is being tested. The device allows cell administration without stopping patient respiration, improving the procedure. Enrollment for the DOSED study is anticipated to begin in June.

Financial Stability

Lineage reported a cash position of $47.9 million as of March 31, 2025, expected to support operations into Q1 2027. The company also has approximately $37 million in warrant capital and is pursuing additional funding sources.

Lineage Therap (LCTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LCTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2025 (Q2)	-0.03 / -	-0.03	―	―	―
May 13, 2025	2025 (Q1)	-0.03 / -0.02	-0.04	50.00% (+0.02)	―
Mar 10, 2025	2024 (Q4)	-0.03 / -0.02	-0.03	33.33% (<+0.01)	―
Nov 14, 2024	2024 (Q3)	-0.04 / -0.02	-0.04	50.00% (+0.02)	―
Aug 08, 2024	2024 (Q2)	-0.04 / -0.03	-0.03	0.00% (0.00)	―
May 09, 2024	2024 (Q1)	-0.04 / -0.04	-0.03	-33.33% (-0.01)	―
Mar 07, 2024	2023 (Q4)	-0.04 / -0.03	-0.03	0.00% (0.00)	―
Nov 09, 2023	2023 (Q3)	-0.04 / -0.04	-0.04	0.00% (0.00)	―
Aug 10, 2023	2023 (Q2)	-0.04 / -0.03	-0.04	25.00% (+0.01)	―
May 11, 2023	2023 (Q1)	-0.04 / -0.03	-0.04	25.00% (+0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LCTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 13, 2025	$0.47	$0.46	-2.13%
Mar 10, 2025	$0.53	$0.53	0.00%
Nov 14, 2024	$0.88	$0.86	-2.27%
Aug 08, 2024	$0.88	$0.90	+2.27%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lineage Cell Therapeutics, Inc. (LCTX) report earnings?

Lineage Cell Therapeutics, Inc. (LCTX) is schdueled to report earning on Aug 07, 2025, After Close (Confirmed).

What is Lineage Cell Therapeutics, Inc. (LCTX) earnings time?

Lineage Cell Therapeutics, Inc. (LCTX) earnings time is at Aug 07, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LCTX EPS forecast?

LCTX EPS forecast for the fiscal quarter 2025 (Q2) is -0.03.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing